Driehaus Capital Management Reduces $15M in Definium Therapeutics, Inc. ($DFTX)
Key Points
- Driehaus Capital Management changed its Definium Therapeutics, Inc. ($DFTX) stake by 9.6% last quarter, cutting to 5,911,889 shares worth $146.32 million.
- Wall Street's consensus rating on $DFTX is Strong Buy and an average price target of $39.87.
- $DFTX last traded around $24.75.
Driehaus Capital Management trimmed its position in Definium Therapeutics, Inc. ($DFTX) by 9.6% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,911,889 shares of Definium Therapeutics, Inc. after selling 625,313 shares during the quarter. Driehaus Capital Management's holdings in Definium Therapeutics, Inc. were worth $146.32 million as of its most recent filing.
Definium Therapeutics, Inc. ($DFTX) Stock
Definium Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.